Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Effect of high calorie high protein diet versus high calorie,glomerular filtration rate (GFR) based protein intake in non-obese advanced HF patients will be assessed. In this regard, protein intake impact will be measured on muscle mass, physical performance and renal function as main outcome. Rehospitalization, quality of life, depression an inflammatory status are second endpoints.
Patient examinations:
Baseline data will be gathered on demographic and clinical characteristics, medical history, treatments and medications. Before initiating intervention, individuals will be assessed for anemia and 25 (OH) D2 and electrolytes status. Any insufficiency or imbalance will be corrected by drug therapy or supplementation. At baseline and at all visits, half or one month intervals, routine laboratory tests for heart failure patients (including Complete blood count (CBC), electrolytes status, glucose, albumin, cholesterol, triglyceride, blood urea nitrogen (BUN), C-reactive Protein (CRP),creatinine, uric acid, ferritin, 25 (OH) D, B-type natriuretic peptide (BNP), thyroid function, Prealbumin, urine analysis), appetite status and anthropometric measurements (weight, Hip and waist circumference) will be performed. At baseline and by the end of month 6, body composition, muscle mass, hand grip strength, Short Physical Performance Battery (SPPB), plasma lactate and interleukin 6 (IL-6), GFR, depression status and quality of life will be assessed. Follow up duration will be one year for measuring readmission and mortality rate. If a study participant did not attend a visit, a staff of randomized clinical trial (RCT) center will attempt to reach her/him, her/his designated friend or family member by phone call.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| high protein intake | Experimental | Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight) |
|
| GFR based protein intake | Active Comparator | Study participants will receive GFR based protein diet to preserve renal function. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| protein intake | Other | For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline muscle mass at 6 months | muscle mass will be assessed by Dual-Energy X-Ray Absorptiometry (DEXA) | At baseline and after 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline depression status at 6 months | Cardiac Depression Scale (CDS) questionnaire | At Baseline and after 6 months |
| Change from baseline appetite status at 6 months | Simplified Nutritional Appetite Questionnaire (SNAQ) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Data will be kept confidential.
Not provided
Not provided
Not provided
Not provided
Not provided
Study design A randomized, parallel-arm, controlled pilot study is designed. Sample size is determined 50 participants per treatment arm using the stepped rules of thumb, with standardized effect sizes of 0.1 or less and power 80% for main trial (n=100). After baseline assessments, balanced permuted block method will be used for randomization. Concealment of the randomization sequence will be performed by the RCT center of Rajaie Cardiovascular, Medical and Research Center. Intervention will be according to the randomization sequence.
Not provided
Not provided
Not provided
|
| At baseline, in each visit up to 6 months |
| Change from baseline quality of life status at 6 months | Kansas City Cardiomyopathy Questionnaire | AT baseline and after 6 months |
| Mortality rate | Mortality occurrence | Up to 1 year |
| Rehospitalization | Frequency of hospital admission in 1 year | Number of hospital admission will be recorded from date of intervention initiation until 1 year |
| Change from baseline kidney function at 6 months | Glomerular filtration rate (GFR) (WIZARD® Automatic Gamma Counter) will be performed | At baseline and after 6 months |
| Change from baseline handgrip strength at 6 months | Handgrip strength will be measured using hand grip dynamometer | At baseline and after 6 months |
| Change from baseline physical performance at 6 months | SPPB score will be measured for physical performance assessment which includes: gait speed (timed 4-metre walk), sit-to-stand time (timed test of five chair rises), and standing balance (side-by-side stand, tandem and semi-tandem positions) | At baseline and after 6 months |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided